Join Life Science Washington Institute, Life Science Washington, and Otsuka for a VIP Forum March 15 & 16, 2023. Download the Otsuka Factsheet here.
There are two ways to participate in this event:
For more information or questions, contact email@example.com !
Clinical Stage Development (from 1 year prior to IND to Phase 3 Study) for:
Mood/psychotic disorder, impulse/conduct disorder, stress/anxiety disorder, neuropsychiatric symptoms, autism, Tourette syndrome, unmet needs including treatment-resistant patients and add-on therapy
Neurodegenerative disease, seizure disorder, repeat disease, Rett-syndrome, Angelman/Prader-Willi syndrome. Both disease modifier and symptom treatment for major neurology diseases like AD, PD, MS, and orphan neurology diseases.
Glomerular and tubular chronic kidney diseases, immune-mediated kidney diseases, complement-mediated kidney diseases, acute kidney injury, kidney transplant
Systemic lupus erythematosus, rare autoimmune diseases including SLE but not including immuno-oncology.
Digital medicines, digital therapeutics, digital biomarkers and diagnostics, connected care platforms, analytics, remote monitoring, data collection
*Symptomatic and disease-modifying treatments
** Area of Interest TA: psychiatry, neurology, and nephrology